Amylx Pharmaceuticals Inc vs Baidu Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.81 (market cap $2.64B), while Baidu Inc trades at $104.04 (market cap $36.18B). The key difference: Baidu Inc is far larger — about 13.7× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Baidu Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | BIDU | |
|---|---|---|
Market Cap | $2.64B | $36.18B |
Sector | Health | Media |
52-Week High | $24.19 | $162.52 |
52-Week Low | $7.82 | $86.76 |
Enterprise Value | $2.39B | $32.81B |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Baidu (BIDU) trades at $103.7, down 5.3% in the last session, reflecting bearish technical signals and recent earnings volatility. The stock shows weak profitability with a net margin of 1.02% and elevated P/E of 78.19, though it trades below book value. Recent news highlights autonomous vehicle testing in London and an upcoming Q2 2026 earnings report on August 18, 2026 (PRNewsWire, 2026-07-31).
Outlook is mixed: strong analyst buy consensus (75.47%) and a $169.80 price target suggest upside, but declining revenue, negative cash flows, and China market risks pose headwinds. AI initiatives offer growth potential, but investors face execution and macroeconomic uncertainties.
Trailing returns across standard periods
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.
Read more on BIDU →